A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

PURPOSE: Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/ MEK signaling. We evaluated the safety and efficacy of the VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors and DTC. PATIENTS AND METHODS: Patients...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Kurzrock, Razelle, Ball, Douglas W., Zahurak, Marianna L., Nelkin, Barry D., Subbiah, Vivek, Ahmed, Shabina, O’Connor, Ashley, Karunsena, Enusha, Parkinson, Rose M., Bishop, Justin A., Ha, Yoonji, Sharma, Rajni, Gocke, Christopher D., Zinner, Ralph, Rudek, Michelle A., Sherman, Steven I., Azad, Nilofer S.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038784/
https://ncbi.nlm.nih.gov/pubmed/31186313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1881
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker